Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
48
AZN Quote, Financials, Valuation and Earnings
Last price:
$72.63
Seasonality move
:
5.75%
Day range:
$72.42 - $74.01
52-week range:
$62.75 - $87.68
Dividend yield:
2.14%
P/E ratio:
32.20x
P/S ratio:
4.19x
P/B ratio:
5.53x
Volume:
3.2M
Avg. volume:
5.6M
1-year change:
7.96%
Market cap:
$225.1B
Revenue:
$54.1B
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.7B | $1.10 | 7.95% | 57.32% | $85.19 |
|
AMGN
Amgen
|
$8.1B | $4.27 | 8.14% | 257.4% | $315.95 |
|
GSK
GSK PLC
|
$9.7B | $1.01 | 4.35% | 57.14% | $43.42 |
|
JNJ
Johnson & Johnson
|
$21.6B | $2.64 | 1.23% | 96.75% | $169.07 |
|
LLY
Eli Lilly and
|
$12.8B | $4.69 | 45.83% | 90.33% | $1,010.47 |
|
MRK
Merck &
|
$15.6B | $2.14 | -1.15% | 13.5% | $112.07 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$72.60 | $85.19 | $225.1B | 32.20x | $1.05 | 2.14% | 4.19x |
|
AMGN
Amgen
|
$306.92 | $315.95 | $164.9B | 40.65x | $2.38 | 2.98% | 4.96x |
|
GSK
GSK PLC
|
$37.87 | $43.42 | $77.2B | 23.92x | $0.40 | 4.11% | 1.95x |
|
JNJ
Johnson & Johnson
|
$153.25 | $169.07 | $369.3B | 26.47x | $1.24 | 3.24% | 4.19x |
|
LLY
Eli Lilly and
|
$805.23 | $1,010.47 | $723.2B | 68.76x | $1.50 | 0.67% | 16.16x |
|
MRK
Merck &
|
$87.12 | $112.07 | $220.1B | 12.95x | $0.81 | 3.63% | 3.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.27% | -0.160 | -- | 0.74x |
|
AMGN
Amgen
|
91.09% | 0.284 | 43.85% | 0.84x |
|
GSK
GSK PLC
|
53.74% | -0.068 | 29.19% | 0.49x |
|
JNJ
Johnson & Johnson
|
33.88% | 0.428 | 10.52% | 0.86x |
|
LLY
Eli Lilly and
|
70.33% | 0.800 | 5.05% | 0.59x |
|
MRK
Merck &
|
44.49% | 0.248 | 15.58% | 0.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
JNJ
Johnson & Johnson
|
$15.4B | $3.8B | 13.3% | 19.98% | 17.87% | $4.8B |
|
LLY
Eli Lilly and
|
$11.1B | $5.8B | 25.09% | 80.24% | 38.89% | $726.6M |
|
MRK
Merck &
|
$11.8B | $4.3B | 21.67% | 40.25% | 28.79% | $2.5B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 6.9%. AstraZeneca PLC's return on equity of 17.77% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $85.19, signalling upside risk potential of 17.35%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 2.94%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 AMGNAmgen9 14 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.14%. Amgen offers a yield of 2.98% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Amgen quarterly revenues of $9.1B. AstraZeneca PLC's net income of $1.5B is higher than Amgen's net income of $627M. Notably, AstraZeneca PLC's price-to-earnings ratio is 32.20x while Amgen's PE ratio is 40.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.19x versus 4.96x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.19x 32.20x $14.9B $1.5B AMGNAmgen4.96x 40.65x $9.1B $627M
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 5.1%. AstraZeneca PLC's return on equity of 17.77% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $85.19, signalling upside risk potential of 17.35%. On the other hand GSK PLC has an analysts' consensus of $43.42 which suggests that it could grow by 14.66%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 GSKGSK PLC2 3 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.135%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.14%. GSK PLC offers a yield of 4.11% to investors and pays a quarterly dividend of $0.40 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.5B is higher than GSK PLC's net income of $530.1M. Notably, AstraZeneca PLC's price-to-earnings ratio is 32.20x while GSK PLC's PE ratio is 23.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.19x versus 1.95x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.19x 32.20x $14.9B $1.5B GSKGSK PLC1.95x 23.92x $10.4B $530.1M
-
Which has Higher Returns AZN or JNJ?
Johnson & Johnson has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 15.24%. AstraZeneca PLC's return on equity of 17.77% beat Johnson & Johnson's return on equity of 19.98%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B JNJJohnson & Johnson68.35% $1.41 $108.1B -
What do Analysts Say About AZN or JNJ?
AstraZeneca PLC has a consensus price target of $85.19, signalling upside risk potential of 17.35%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 10.32%. Given that AstraZeneca PLC has higher upside potential than Johnson & Johnson, analysts believe AstraZeneca PLC is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 JNJJohnson & Johnson7 13 0 -
Is AZN or JNJ More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.
-
Which is a Better Dividend Stock AZN or JNJ?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.14%. Johnson & Johnson offers a yield of 3.24% to investors and pays a quarterly dividend of $1.24 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or JNJ?
AstraZeneca PLC quarterly revenues are $14.9B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AstraZeneca PLC's net income of $1.5B is lower than Johnson & Johnson's net income of $3.4B. Notably, AstraZeneca PLC's price-to-earnings ratio is 32.20x while Johnson & Johnson's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.19x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.19x 32.20x $14.9B $1.5B JNJJohnson & Johnson4.19x 26.47x $22.5B $3.4B
-
Which has Higher Returns AZN or LLY?
Eli Lilly and has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 32.59%. AstraZeneca PLC's return on equity of 17.77% beat Eli Lilly and's return on equity of 80.24%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B LLYEli Lilly and82.24% $4.88 $47.9B -
What do Analysts Say About AZN or LLY?
AstraZeneca PLC has a consensus price target of $85.19, signalling upside risk potential of 17.35%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 25.49%. Given that Eli Lilly and has higher upside potential than AstraZeneca PLC, analysts believe Eli Lilly and is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 LLYEli Lilly and16 4 0 -
Is AZN or LLY More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.
-
Which is a Better Dividend Stock AZN or LLY?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.14%. Eli Lilly and offers a yield of 0.67% to investors and pays a quarterly dividend of $1.50 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or LLY?
AstraZeneca PLC quarterly revenues are $14.9B, which are larger than Eli Lilly and quarterly revenues of $13.5B. AstraZeneca PLC's net income of $1.5B is lower than Eli Lilly and's net income of $4.4B. Notably, AstraZeneca PLC's price-to-earnings ratio is 32.20x while Eli Lilly and's PE ratio is 68.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.19x versus 16.16x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.19x 32.20x $14.9B $1.5B LLYEli Lilly and16.16x 68.76x $13.5B $4.4B
-
Which has Higher Returns AZN or MRK?
Merck & has a net margin of 10.07% compared to AstraZeneca PLC's net margin of 23.96%. AstraZeneca PLC's return on equity of 17.77% beat Merck &'s return on equity of 40.25%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC81.7% $0.48 $69.5B MRKMerck &75.5% $1.48 $83.5B -
What do Analysts Say About AZN or MRK?
AstraZeneca PLC has a consensus price target of $85.19, signalling upside risk potential of 17.35%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 28.64%. Given that Merck & has higher upside potential than AstraZeneca PLC, analysts believe Merck & is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 MRKMerck &11 9 0 -
Is AZN or MRK More Risky?
AstraZeneca PLC has a beta of 0.485, which suggesting that the stock is 51.487% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.
-
Which is a Better Dividend Stock AZN or MRK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.14%. Merck & offers a yield of 3.63% to investors and pays a quarterly dividend of $0.81 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRK?
AstraZeneca PLC quarterly revenues are $14.9B, which are smaller than Merck & quarterly revenues of $15.6B. AstraZeneca PLC's net income of $1.5B is lower than Merck &'s net income of $3.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 32.20x while Merck &'s PE ratio is 12.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.19x versus 3.45x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.19x 32.20x $14.9B $1.5B MRKMerck &3.45x 12.95x $15.6B $3.7B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
100
DLICY alert for Apr 2
Dai-ichi Life Holdings [DLICY] is down 3.14% over the past day.
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Sell
15
PCVX alert for Apr 2
Vaxcyte [PCVX] is down 0.31% over the past day.
